Compare VTMX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTMX | IRON |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | Mexico | United States |
| Employees | 107 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2023 | N/A |
| Metric | VTMX | IRON |
|---|---|---|
| Price | $31.42 | $78.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $30.50 | ★ $110.08 |
| AVG Volume (30 Days) | 64.3K | ★ 537.0K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $271,805,969.00 | N/A |
| Revenue This Year | $13.43 | N/A |
| Revenue Next Year | $9.87 | N/A |
| P/E Ratio | $45.56 | ★ N/A |
| Revenue Growth | ★ 11.74 | N/A |
| 52 Week Low | $21.30 | $30.82 |
| 52 Week High | $32.68 | $99.50 |
| Indicator | VTMX | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 48.41 |
| Support Level | $31.20 | $74.42 |
| Resistance Level | $32.68 | $82.26 |
| Average True Range (ATR) | 0.59 | 3.70 |
| MACD | -0.05 | 0.83 |
| Stochastic Oscillator | 25.70 | 72.31 |
Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.